CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The encouraging results of the phase 3 ORIENT-11 trial, which included 397 patients with previously untreated, locally advanced metastatic non-squamous NSCLC without sensitizing EGFR or ALK aberrations, were published in the Journal of Thoracic Oncology.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
